Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average t	ourden									
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bronstein Ben (Last) (First) (Middle) C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE (Street) LEXINGTON MA 02421 (City) (State) (Zip)				3 0	2. Issuer Name and Ticker or Trading Symbol Aldeyra Therapeutics, Inc. [ALDX] 3. Date of Earliest Transaction (Month/Day/Year) 06/08/2017 4. If Amendment, Date of Original Filed (Month/Day/Year)						6. In	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					2A. Deemed Execution Date,		3. Transacti	4. Securi Dispose tr. 5)	ities Acquire d Of (D) (Ins	ed (A) or tr. 3, 4 and	5. Amount of Securities Fo Beneficially (D)		Ownership orm: Direct) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	on 3A. Deemed Execution Date		4. Transaction Code (Instr.			uired, Disposed of, s, options, convertil 6. Date Exercisable and Expiration Date (Month/Day/Year)				8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	· V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	•			
Stock Option (Right to Buy)	\$5.15	06/08/2017		A		17,776		(1)	06/07/2027	Common Stock	17,776	\$0.00	17,776	D	
Stock Option (Right to Buy)	\$5.15	06/08/2017		A		2,222		(2)	06/07/2027	Common Stock	2,222	\$0.00	2,222	D	
Stock Option (Right to	\$5.15	06/08/2017		A		1,481		(3)	06/07/2027	Common Stock	1,481	\$0.00	1,481	D	

Explanation of Responses:

- 1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
- 2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
- 3. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.

Remarks:

/s/ Ben Bronstein

06/12/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.